Guggenheim Sticks to Its Buy Rating for AstraZeneca (AZN)
In a report released today, Seamus Fernandez from Guggenheim reiterated a Buy rating on AstraZeneca, with a price target of p16,000.00.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Fernandez covers the Healthcare sector, focusing on stocks such as Bristol-Myers Squibb, Vaxcyte, and Structure Therapeutics, Inc. Sponsored ADR. According to TipRanks, Fernandez has an average return of 26.8% and a 61.49% success rate on recommended stocks.
In addition to Guggenheim, AstraZeneca also received a Buy from Jefferies’s Michael Leuchten in a report issued on March 6. However, on March 5, Deutsche Bank maintained a Sell rating on AstraZeneca (LSE: AZN).
Based on AstraZeneca’s latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of p15.5 billion and a net profit of p2.33 billion. In comparison, last year the company earned a revenue of p14.54 billion and had a net profit of p1.46 billion
Based on the recent corporate insider activity of 9 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of AZN in relation to earlier this year.
Read More on GB:AZN:
Disclaimer & DisclosureReport an Issue
- AstraZeneca Sets Digitally Enabled 2026 AGM with Key Governance and Capital Votes
- AstraZeneca price target raised to 16,000 GBp from 15,500 GBp at Guggenheim
- AstraZeneca, Daiichi Sankyo announce priority review for Enhertu sBLA
- Controversial Prasad leaving FDA, NYT reports
- AstraZeneca’s AZD5004 Formulation Trial: Early Data Point for Long-Term Pipeline Value
